Suppliers / Boehringer Ingelheim Pharma Gmbh

Boehringer Ingelheim Pharma Gmbh

United Arab Emirates 2 duplicate records merged Updated 9 July 2026

Boehringer Ingelheim Pharma Gmbh is an API and finished-dose manufacturer based in United Arab Emirates. It holds 6 active US drug master files and one valid CEP across a filed portfolio of 15 molecules. Its filings concentrate with MHRA (UK), AIFA (IT) and FAMHP (BE). Its GMP standing is certified by ZLG (DE), EMA and ANVISA (Brazil), among 10 authorities. Its most recent recorded inspection, by US FDA, closed on 12 November 2024 as NAI.

6
active US DMFs
1
valid CEPs
12
registered plants 2 with an FDA FEI number
3,643
filings across 42 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
2 of 2 confirmed
Inspections
8 of 8 confirmed
EU GMP
1 of 1 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026. EudraGMDP (MIA + third-country GMP certs), read 4 May 2026.

Inspection history

  • 12 November 2024 NAI US FDA
  • 4 June 2024 VAI US FDA
  • 30 June 2023 VAI US FDA
  • 2 March 2023 NAI US FDA
  • 4 November 2022 VAI US FDA
  • 16 September 2022 NAI US FDA
  • 22 July 2022 VAI US FDA
  • 7 October 2021 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
Biberach, United Arab Emirates Not on file
Ingelheim am Rhein, United Arab Emirates Not on file
Ingelheim am Rhein, United Arab Emirates Not on file
Biberach, United Arab Emirates Not on file
D-88397 Biberach an der Riss, United Arab Emirates Not on file
Koropi, United Arab Emirates Not on file

6 further sites are on record.

What they file, and where

Molecule Regulators Docs
Afatinib Dimaleate SFDA (Saudi Arabia) 1
Albuterol US FDA 1
Atropine SFDA (Saudi Arabia) 1
Clenbuterol EDQM 1
Dabigatran Etexilate SFDA (Saudi Arabia) 1
Empagliflozin SFDA (Saudi Arabia) 1
Epinastine US FDA 1
Epinephrine SFDA (Saudi Arabia) 1
Ipratropium US FDA 1
Methocarbamol US FDA 1
Show all 15 molecules on file
Phenylephrine SFDA (Saudi Arabia) 1
Pramipexole US FDA 1
Repaglinide US FDA 1
Telmisartan SFDA (Saudi Arabia) 1
Tiotropium SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Acetylsalicylic Acid finished dose Ambroxol finished dose Amlodipine finished dose Ampicillin finished dose Bisacodyl finished dose Bromhexine finished dose Budesonide finished dose Caffeine finished dose Capecitabine finished dose Chlorthalidone finished dose Clarithromycin finished dose Codeine finished dose
Show 30 more molecule pages
Dextromethorphan finished dose Diazepam finished dose Doxycycline finished dose Duloxetine finished dose Empagliflozin API Hydrochlorothiazide finished dose Indomethacin finished dose Irbesartan finished dose Ivermectin finished dose Lansoprazole finished dose Linagliptin finished dose Meloxicam finished dose Metformin finished dose Metronidazole finished dose Mycophenolate Mofetil finished dose Nitrofurantoin finished dose Olanzapine finished dose Omeprazole finished dose Perindopril finished dose Phenylephrine API Pramipexole API Quetiapine finished dose Ramipril finished dose Ranitidine finished dose Salbutamol API Saxagliptin finished dose Sitagliptin finished dose Tamsulosin finished dose Telmisartan API Tiotropium API

Filings and GMP by regulator

Regulator Filings GMP certificates
MHRA (UK) 383 None
AIFA (IT) 356 None
FAMHP (BE) 332 None
Health Canada 297 None
EMA 204 12
DKMA (DK) 183 None
ZLG (DE) None 16
ANVISA (Brazil) None 11
ANSM (FR) None 7
US FDA None 3
COFEPRIS (MX) None 2
NCELS (KZ) None 2
NAFDAC (NG) None 1
INVIMA (CO) None 1
AEMPS (ES) None 1

Scale

Year Revenue Exports Destinations
2022 $770.0B Not reported Not reported

Export figures are customs aggregates. We do not publish the identity of any buyer.

Comparing suppliers?

Choose your molecules and target markets. Boehringer Ingelheim Pharma Gmbh comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was NAI, on 12 November 2024.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates
Company filings
Revenue as reported